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A B S T R A C T
Over decades dependency of humans on the drugs has become indispensable and irreplaceable. Thus, each year
many new drugs are licensed. Nonetheless, drugs undergo rigorous testing and analysis to be available globally in
economic price for the suitability of patients with different age and physiological conditions. The testing of drugs
include phase I clinical trial using small group of 20–100 healthy volunteers for safety, pharmacology and effi-
cacy; phase II clinical trial using 100–500 volunteer patients to optimize effective dose, dose interval, safety
analysis and mode of delivery such as oral or intravenous; phase III clinical trial using 1000–5000 in a larger
population of patients globally at different international places to collect sufficient safety and efficacy data for
patenting and licencing. Moreover, thousands of drugs fail to achieve these objectives. Therefore, this mini-review
intends to critically examine and assimilate the clinical applications of selected complex repurposed small drug
molecules which are in different phase of trials for treating viral infection including complications due to COVID-
19: (a) Remdesivir, (b) Galidesivir, (c) Favipiravir, (d) Baricitinib, and (e) Baloxavir.
1. Introduction
Currently coronavirus disease 2019 (COVID-19) has become a global
pandemic. The number of people being infected by this highly contagious
virus is increasing rapidly and continuously [1–3]. However, to date no
drug, vaccine or monoclonal antibodies have been approved for the
treatment of COVID-19 except few for emergency use. Therefore,
development of effective vaccines remains a vital importance. However,
scientists and researchers across the globe have been investigating
pre-existing anti-viral drugs that might be repurposed to fight COVID-19.
Moreover, some small drug molecules such as Remdesivir, Galidesivir,
Favipiravir, Baricitinib, and Baloxavir are currently under clinical trials
for their application to treat viral infection including complications due
to COVID-19. Therefore, this mini-review aims to survey small drug
molecules Remdesivir, Galidesivir, Favipiravir, Baricitinib and Baloxavir
for their applications to combat viral diseases including COVID-19.
First drug which has been considered for the review is Remdesivir,
showed promising in vitro activity against several strains of coronavirus,
including SAR-CoV-2 in Vero E6 cells with EC50 and EC90 values of 0.77
μM and 1.76 μM, respectively [4]. Thus, it can be a potential drug for
coronavirus. Clinical trials are ongoing to assess both the safety and
anti-viral activity in patients with mild- moderate- and severe- COVID-19
symptoms. The second drug Galidesivir exhibits broad-spectrum antiviral
activity against more than 20 RNA viruses and is extremely important in
the treatment of nine different virus families i.e., Flavivirus, Togavirus,
Bunyavirus, Arenavirus, Paramyxovirus, Coronavirus, Phylovirus,
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Orthomyxovirus and Picornavirus [5–8]. The drug is currently under
clinical investigation for the treatment of Ebola virus disease and yellow
fever [9,10], and has also been reported to be effective in Zika virus
[11–14]. Considering the outbreak of novel coronavirus infection, recent
studies are focusing on repurposing Galidesivir for the treatment of
SARS-CoV-2 [15–18]. The third drug discussed in the line is Favipiravir.
The effective and potent activity of Favipiravir against RNA influenza
viruses makes it a promising drug that could be used for specifically
untreatable RNA viral infections. Recently, Favipiravir showed prom-
ising in-vitro results against SARCoV-2 in early clinical studies [19]. The
fourth drug Baricitinib, is an approved drug in the treatment of rheu-
matoid arthritis. The drug’s anti-inflammatory activity is expected to act
on the inflammatory cascade associated with COVID-19 [20,21]. Its
mode of action and green synthetic routes have been discussed in detail.
The last one Baloxavir, a newly discovered drug to treat influenza A or B,
has been included with its relevant available data. Compared to other
drugs which block release of virus from the infected cell such as neur-
aminidase inhibitor, Baloxavir inhibits influenza virus replication by
stopping synthesis of mRNA [22]. Fig. 1 depict these small drugs mole-
cules and their currently reported clinical significance.
2. Remdesivir
Remdesivir (Fig. 2), formally known as GS-5734, is an investigational
broad-spectrum antiviral agent developed and introduced by Gilead
Sciences [23,24]. It is a prodrug of its parent adenosine analog,
GS-441524. Being a viral RNA-dependent RNA polymerase (RdRP) in-
hibitor, it can be used to treat a variety of RNA virus infections. It has
demonstrated activity against Coronaviridae family (eg. severe acute
respiratory syndrome coronavirus SARSCoV), Paramyxoviridae family
(eg. Nipah virus and Hendra) and Filoviridae family (eg. Ebola virus).
Remdesivir was primarily designed to treat Ebola virus infection, how-
ever, the drug showed poor efficacy in phase III clinical trials and hence,
remained in the research and development (R & D) stage. Recently, the
drug is gaining much attention and is anticipated to be effective for
treating SARS-CoV-2 infection [24–28].
2.1. History of remdesivir
Remdesivir was invented by Gilead Sciences. It has emerged from a
collaboration between Gilead, the U.S. Centers for Disease Control and
Prevention (CDC) and the U.S. Army Medical Research Institute of In-
fectious Diseases (USAMRIID), that was established to identify [29]
family [30]. Initially, a library consisting of approximately 1000 small
molecules was developed that focused on nucleoside analogues. Owing to
poor cell permeability of nucleosides, major attention was given to
modified nucleosides such as monophosphate, ester and phosphor-
amidate prodrugs. These modified nucleosides are more permeable and
metabolized to release phosphorylated or non-phosphorylated nucleo-
side within the cells [31,32]. One such nucleoside was 10-CN modified
adenosine C-nucleoside (GS-441524) and its prodrug GS-5734 was found
quite effective [33]. The study conducted in 2012 reported that
GS-441524 and its S-acyl-2-thioethyl monophosphate prodrug showed
broad activity against a range of RNA viruses including influenza A,
dengue virus type 2, yellow fever virus and SARS [34]. Further, GS-5734
was found active against SARS strain Toronto 2 (IC50 ¼ 2.2 μM) without
showing cytotoxicity toward the host Vero African green monkey kidney
epithelial cells used in the CPE assay. During Ebola outbreak, it was re-
ported that GS-441524 was inactive while GS-5734 successfully reduced
EBOV replication in HeLa cells [35]. With many such studies, scientific
community gained interest in Remdesivir, and it was validated that it
possesses wide antiviral activity against SARS, MERS zoonotic corona-
viruses, circulating human coronaviruses HCoV-OC43 and HCoV-229E,
common agents of the common cold [29,36,37].
Recently, a novel pneumonia caused by an unknown pathogen has
outbreak in Wuhan, China. The pathogen was identified as a strain of
coronavirus named severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) due to close similarities with severe acute respiratory
syndrome coronavirus [38]. Currently, coronavirus disease 2019
(COVID-19) has become a global pandemic [39]. The number of people
being infected by this highly contagious virus is still increasing quickly
[1–3]. In this scenario, physicians are considering “repurposing” several
existing antiviral drugs that are effective in treating related viral in-
fections. Therefore, clinical trials are being accelerated for the various
antiviral medications known for SARS, MERS, HIV/AIDS, malaria etc. [4,
15,40–44] Clinical trials of some small molecule drugs are also being
conducted for the treatment of COVID-19, including Remdesivir.
Remdesivir, showed promising in vitro activity against several strains of
coronavirus, including SAR-CoV-2 in Vero E6 cells with EC50 and EC90
values of 0.77 μM and 1.76 μM, respectively [4]. Thus, it can be a po-
tential drug. Clinical trials are ongoing to assess both the safety and
anti-viral activity in patients with mild-moderate-severe COVID-19.
2.2. Synthesis of Remdesivir
The chemical formula of Remdesivir is C27H35N6O8P. It is a Sp isomer
of compound 8a (Sp and Rp isomers ~1:1, Scheme 1). Stereochemically,
8a can have two configurations; Sp-isomer (8b) and Rp-isomer. The
difference in both isomers lies in the spatial configuration of 2-ethylbu-
tyl-2-aminopropanoate and anisole. Among both, 8b possesses greater
selectivity and therapeutic window desirable for antiviral activity [45].
Fig. 1. Schematic representation of small drug molecules and their currently
reported clinical significance.
Fig. 2. Structure of remdesivir.
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After an extensive literature survey, three synthesis route maps were
identified for its development which have been discussed below.
Route 1
The first synthetic route to Remdesivir was proposed by Richard L.
Mackman (Scheme 1) [35,45–49]. The scheme was initiated with the
glycosylation reaction of 2,3,5-tri-O-benzyl-D-ribono-1,4-lactone (2)
with 7-bromopyrrolo[2,1-f][1,2,4]triazine-4-amine (1a), followed by the
addition of trimethylsilyl chloride (TMSCl) and n-BuLi or NaH and 1,
2-bis(chlorodimethylsilyl)ethane for the N-protection of 1a. Compound
(3) was obtained after metal-halogen exchange in tetrahydrofuran (THF)
at 78 C. Next, hydroxyl nucleoside 3 was cynated using trimethylsilyl
cyanide (TMSCN) mediated by BF3  Et2O in dichoromethane at 78
C
to afford cyano nucleoside, and the desired product (R)-isomer (4) is
separated after chromatography in 58% yield. Next, deprotection of
benzyl protecting groups was carried out in CH2Cl2 and BCl3 to form
compound 5, which was combined with 7 (a diastereomer mixture of the
phosphoramidyl chloride hydrochloride prodrug portion) to obtain
compound 8a in 21% yield as ~1:1 mixture of diastereomers. The tar-
geted drug Remdesivir (8b) was finally obtained after chiral HPLC of
compound 8a [44,45].
Route 2
Later, Richard L. Mackman and Warren, T. K. reported a modified
route for the synthesis of Remdesivir (Scheme 2) [35,46–49]. This
method provides a diastereoselective synthesis through selective crys-
tallization of phosphorus coupling partner 11a-Sp, hence, eliminating
preparative scale chiral chromatography. In this method, 7-iodopyrrolo
[2,1-f][1,2,4]triazin-4-amine (1b) was treated with TMSCl, PhMgCl
and isopropylmagnesium chloride lithium chloride (i-PrMgCl⋅LiCl) in
THF at 20 C and then condensed with lactone (2) to obtain adduct 3.
Cyano group was introduced using TMSCN, trifluoromethanesulfonate
(TMSOTf) and trifluoromethanesulfonic acid (TfOH) at 78 C in
dichloromethane to produce corresponding epimeric cyanide. This was
followed by the chromatographic separation of desired (R)-isomer (4).
Next, triol (5) was generated through benzylation in presence of BCl3 in
CH2Cl2 at 20
C. The diol moiety of (5) was protected with 2,2-dime-
thoxypropane using H2SO4 in acetone to produce the isopropylidene
derivative (9). Finally, (9) was condensed with amidophosphate (11a) in
presence of MgCl2 and N,N-diisopropylethylamine in acetonitrile to give
protected Remdesivir (12), which is deprotected with aqueous HCl in
THF to yield the target drug Remdesivir (8b) [4,45].
Route 3
Gilead Sciences introduced another synthetic route to form Remde-
sivir (Scheme 3) [35,46–50]. Firstly,N-protection of 7-iodopyrrolo[2,1-f]
[1,2,4]triazin-4-amine (1b) was done using TMSCl and PhMgCl followed
by metal-halogen exchange with i-PrMgCl⋅LiCl in THF at 15 C. Sub-
sequently, persilylated lactone (13) was added along with LaCl3⋅2LiCl in
THF at 15 C produces lactol intermediate (14). The cyanation and
selective desilylation of lactol (14) with TMSCN using TMSOTf and tri-
fluoroacetic acid in CH2Cl2 at 40
C yields the corresponding epimeric
cyanide. Next, preparative HPLC was done to separate the desired
(R)-isomer (15). Next, (15) is condensed with either amidophosphate
(11a) in presence of MgCl2 and (i-Pr)2NEt in THF or with penta-
fluorophenyl protected derivative (11b) in the presence of
tert-butylmagnesium chloride (tBuMgCl) in THF to give silylated
Scheme 1. Route 1 for the Synthesis of Remdesivir.
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compound (16). Finally, the target Remdesivir (8b) was obtained after
deprotection of (16) using HCl, tetrabutylammonium fluoride (TBAF), KF
or pyridinium hydrofluoride [4,44].
2.3. Mode of action
Within the host, an antiviral chemotherapeutic intervention generally
attacks either specific viral enzymes or weak point of virus replication,
such as RdRp. Remdesivir is a monophosphoramidate prodrug of an
adenosine nucleoside analogue. Nucleoside analogues often classified
into three classes, i.e., mutagenic nucleosides, obligate chain terminators
and delayed chain terminators [51]. Mutagenic nucleosides are those
that attacks the viral reliance over RdRp to catalyze the replication of the
RNA genome from the native RNA template. Obligate chain terminators
include nucleotides that once incorporated, directly inhibits further DNA
primer extension. Remdesivir is a delayed chain terminator, that block
transcription and its 30-hydroxyl group can still form phosphodiester
bond with further incorporated nucleotide [52].
Remdesivir enters the host cell as a prodrug. Within the cell, it me-
tabolizes into alanine metabolite, GS-704277, further converted into
nucleotide monophosphate (NMP) and finally dephosphorylated to
active nucleoside triphosphate (NTP), Fig. 3 [35]. This conversion to
NMP takes place through a series of hydrolytic steps that begins with
esterase-mediated hydrolysis of the amino acid ester to form carboxylate
that undergoes internal cyclization to phosphonate and eliminate phen-
oxide. Cyclic anhydride thus formed, being unstable, gets hydrolyzed to
alanine metabolite GS-704277 whose P–N bond is hydrolyzed by
phosphoramidase-type enzymes to give highly polar NMP. Highly polar
Scheme 2. Route 2 for the synthesis of Remdesivir.
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nature of NMP restricts its reverse diffusion across the cell membrane.
Now, NMP is converted to active NTP analogue via phosphorylation
events by host cell kinases [30]. NTP and adenosine triphosphate (ATP)
have a similar structure and competes with each other to bind to the viral
RdRp with nearly same efficiencies, therefore NTP is used by the viral
RdRp which results in premature termination of RNA synthesis, halting
the growth of the RNA strand after a few more nucleotides are added
[45]. G€otte et al. reported that, in case of EBOV RdRp, NTP incorporated
into the RNA synthesis chain at position i does not affect the incorpo-
ration of subsequent nucleotide at position iþ1 [53]. However, RNA
Scheme 3. Route 3 for the synthesis of Remdesivir.
Fig. 3. Intracellular processing of the prodrug Remdesivir (GS-5734). Reproduced with permissions from (ref [35]) Nature 508, 402–405 (2014). Copyright: Springer
Nature, 2014.
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chain termination takes place at a position few bases downstream of
position i (predominantly at position iþ5). This process is called “delayed
chain termination”.
3. Galidesivir
Galidesivir (BCX4430) is an adenosine analog in which nitrogen at
position 7 on the base is substituted by carbon and oxygen on position 1
on ribose ring is substituted by nitrogen (Fig. 4) [9]. Galidesivir exhibits
broad-spectrum antiviral activity against more than 20 RNA viruses and
is extremely important in the treatment of nine different virus families
i.e., flavivirus, togavirus, bunyavirus, arenavirus, paramyxovirus, coro-
navirus, phylovirus, orthomyxovirus and picornavirus [5–8]. The drug is
currently under clinical investigation for the treatment of Ebola virus
disease and yellow fever [9,10]. Recently, Galidesivir has also been re-
ported to be effective in Zika and tick-borne flavivirus infection models
[11–14].
3.1. History of galidesivir
Galidesivir was developed by BioCryst under broad-spectrum anti-
viral (BSAV) research program which aims to synthesize broad-spectrum
parenteral and oral therapeutics for viruses that are hazardous to human
health and national security. BioCryst developed this drug in collabora-
tion with US Government Agencies. In 2013, National Institute of Allergy
and Infectious Diseases (NIAID) and BioCryst agreed on a contract to
develop Galidesivir as a treatment for Marburg virus disease and for
other filoviruses, such as Ebola virus. Later in March 2015, Biomedical
Advanced Research and Development Authority (BARDA)within the U.S.
Department of Health & Human Services’ Office of the Assistant Secre-
tary for Preparedness and Response (ASPR) awarded BioCryst a contract
for the continued development of Galidesivir as a potential treatment for
diseases caused by RNA pathogens [46]. Recently, Galidesivir has been
approved in Phase I clinical safety and pharmacokinetics trials in which it
was administered in healthy subjects through intravenous as well as
intramuscular manner. During animal studies, there are confirmed sur-
vival benefits associated with the drug against a variety of serious
pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses
[54].
Considering the outbreak of novel coronavirus 2019 infection, recent
studies are focusing on repurposing Galidesivir for the treatment of
SARS-CoV-2 [15–18]. In this regard, BioCryst has initiated enrolment of a
randomized, double-blind, placebo-controlled clinical trial to evaluate
the safety, clinical impact and antiviral effects of Galidesivir in patients
infected with COVID-19. This trial (NCT03891420) has been funded by
NIAID as a part of the National Institutes of Health.
3.2. Synthesis of galidesivir
Warren et al. synthesized BCX4430 as part of a small-molecule library
designed to prevent viral RNA polymerase activity [5]. The synthetic
route has been depicted in Scheme 4 that comprises total seven synthetic
steps starting from BCX1777 in 22–25% overall isolated yield. The syn-
thetic of BCX1777 was reported by Evans et al. [55].
This method involved the condensation in the basic conditions of 5-
methylol-3,4-pyrrolidine glycol and base. Further, the method requires
the protection and deprotection of various functional groups using
blocking agents which makes the process tedious and time consuming.
Lately, US Patent No. 6458799 also reported a synthetic route for
direct transformation of nucleoside analog (Scheme 5) [56]. In this route
the starting material, BCX1777 was acetylated using acetic anhydride in
pyridine to give tri-O-acetate (7) which was later chlorinated using
dimethylchloromethyleneammonium chloride to give 8. Ammonolysis of
8 yields BCX4430 by cleaving the acetate protecting groups. In 2017 a
patent was published describing the synthetic methods for the prepara-
tion of Galidesivir [57].
3.3. Mode of action
As mentioned earlier, in Galidesivir there is a structural change in
furanose moiety of adenosine to an azasugar ring. This change causes
alteration in steric and electrostatic interactions which affect the
conformation of the sugar. The conformational changes influence the
incorporation of nucleotide and chain extension by the viral RNA-
dependent RNA polymerases resulting in non-obligate chain termina-
tion of viral RNA synthesis [5,9,58].
The mechanism of chain termination requires phosphorylation of
parent BCX4430 to BCX4430-triphosphate (BCX4430-TP) through
cellular kinases phosphorylate. Then, after pyrophosphate cleavage,
BCX4430-monophosphate (BCX4430-MP) is incorporated into a growing
viral RNA chain leading to premature termination of transcription and
replication of viral RNA. It has been reported that the chain termination
takes place two bases after insertion of BCX4430-MP probably due to
inhibitory stereochemical distortions of the growing RNA chain. This
mechanism has been demonstrated in vitro using a hepatitis C RNA po-
lymerase assay by Warren et al. (Fig. 5) [5].
4. Favipiravir
Favipiravir (chemical name: 6-fluoro-3-hydroxypyrazine-2-carboxa-
mide) (Fig. 6) is a pyrazine based antiviral drug discovered by Japa-
nese company Toyama Chemical Co., Ltd for the treatment of influenza
virus. This drug was firstly synthesized in 2000 by Toyama Chemical
(Fujifilm group) and approved for medical use in 2014. After two year in
2016 this drug was licensed to Chinese company Zhejiang Hisun Phar-
maceuticals Co. and in 2019 it became a generic drug. Favipiravir was
found to be effective against various types, subtypes and strains of
influenza viruses including the strains which are resistant to existing
marketed anti-influenza drugs. This drug is found to be a selective in-
hibitor of RND-dependent RNA polymerase, various other RNA viruses
such as Ebola virus, West Nile virus, Norwalk virus, and RNA viruses
which are responsible for fatal haemorrhagic fever. Therefore, the
effective and potent activity of Favipiravir against RNA influenza viruses
makes it a promising drug that could be used for specifically untreatable
RNA viral infections. Recently, Favipiravir showed promising in-vitro
results against SARCoV-2 in early clinical studies [19], although high
concentration (EC50 ¼ 61.88 μM) of drug dose was required in compar-
ison with chloroquine or remedisivir [59]. In a study Favipiravir
exhibited in-vitro antiviral activity against Covid-19 by less than 50% at
concentration up to 100 mM and at 21 mM concentration clinically in
patients who has given the dose of Favipiravir [60]. Very recently,
Glenmark pharmaceuticals has come up with top-line results of Favipir-
avir against mild to moderate Covid-19 patients from phase-3 clinical
trial conducted across seven clinical sites in India. The results of phase-3
clinical trial displayed numerical developments for the primary effi-
ciency endpoint with 28.6% rapid viral clearance in the overall popula-
tion [61].
4.1. Synthesis of Favipiravir
The first synthesis of Favipiravir was carried out by Furuta and Egawa
in 2000 in seven steps [62]. The synthesis was started by the methylationFig. 4. Structure of galidesivir.
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of 3-aminopyrazine-2-carboxylic acid using methanol and sulphuric acid.
Then pyrazine moiety was brominated at 6-position followed by con-
version of amino group into methoxy group. Afterwards Pd-catalyzed
amination was carried out using diphenylmethanimine in presence of
(S)-BINAP. The amino group was converted into a fluoro group in pres-
ence of Olah reagent and finally favipiarvir was obtained by treating
6-fluoro-3-methoxypyrazine-2-carboxamide with sodium iodide and tri-
methylsilyl chloride (TMSCl) (Scheme 6).
After fourteen years of Furuta and Egawa report in 2014 Shi et al.
reported a highly improved protocol for the preparation of Favipiravir
which involves only four steps [63]. This group started the synthesis of
Favipiravir using 3-hydroxypyrazine-2-carboxylic acid as starting mate-
rial. Initially, the amidation of 3-hydroxypyrazine-2-carboxylic acid was
done to form 3-hydroxypyrazine-2-carboxamide. The reaction of
3-hydroxypyrazine-2-carboxamide with potassium nitrite in presence of
H2SO4 delivered 3-hydroxy-6-nitropyrazine-2-carboxamide. Reduction
of 3-hydroxy-6-nitropyrazine-2-carboxamide using Raney Ni and hy-
drazine followed by fluorination in presence of Olah reagent delivered
the Favipiravir (Scheme 7).
Watanabe and co-workers in 0215 patented a nontrivial method for
the synthesis of Favipiravir [64]. They have used ethyl 2,
2-diethoxyacetate as starting material which was initially converted
into isoxazole derivative which was converted into isoxazolo[4,5-b]
pyrazine compound in presence of PTSA and then subsequent treatment
of isoxazolo[4,5-b]pyrazine derivative with sodium hydroxide and
DOWEX delivered 6-fluoro-3-hydroxypyrazine-2-carbonitril. Finally,
oxidative amidation of 6-fluoro-3-hydroxypyrazine-2-carbonitrile in
presence of alkaline hydrogen peroxide furnished Favipiravir (Scheme
8).
In 2017 Liu et al. disclosed the synthesis of favipravir starting from 3-
aminopyrazine-2-carboxylic acid [65]. Initial few steps of this protocol
were similar to that of Furuta et al. till the formation of key intermediate
methyl 2-amino-5-bromobenzoate. This intermediate was then subjected
to a sequence of reactions such as conversion of amino group into hy-
droxyl group followed by methylation to obtain methyl 5-bromo-2-me-
thoxybenzoate. Reaction of methyl 5-bromo-2-methoxybenzoate with
POCl3 in presence of DIEA delivered 3,6-dichloropyrazine-2-carbonitrile.
Finally, one-pot treatment of 3,6-dichloropyrazine-2-carbonitrile with
potassium fluoride in presence of Bu4NBr followed by reaction with
hydrogen peroxide using potassium carbonate base and then with so-
dium bicarbonate resulted in the targeted Favipiravir (Scheme 9).
Scheme 4. Synthetic route of BCX4430 (ref [2]).
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In 2019 Guo et al. developed a new approach [66] which involved the
conversion of pyrazin-2-amine into Favipiravir through a number a re-
actions such as regioselective chlorination, bromination, Pd-catalyzed
cyanantion, Sandmeyer reaction for conversion of amine group into
chlorine via diazotization, replacement of chlorine group with fluorine
through aromatic nucleophilic substitution reaction followed by hydro-
lysis reaction, etc. Finally, thus obtained 3,6-difluoropyrazine-2-carboxa-
mide was converted into Favipiravir in presence of sodium bicarbonate
and 1,4-dioxane-water system (Scheme 10).
4.2. Mode of action
Favipiravir showed different mechanisms of action compared to
existing antiviral drugs. Studies exposed that active Favipiravir-RTP
selectively binds to RNA-dependent RNA-polymerase (RdRp) thereby
precludes replication of viral genome [67]. Favipiravir-RTP assimilation
to newly developed RNA blocks the RNA strand elongation and viral
proliferation. It has also found in studies that the existence of purine
analogues can reduce antiviral activity of Favipiravir, revealing compe-
tition of favipravir-RTP with purine nucleotide for RdRp binding [68,69].
5. Baricitinib
Baricitinib (C16H17N7O2S) (Fig. 7), is a drug for the treatment of
rheumatoid arthritis (RA) [69] in adults whose disease was not well
controlled using RA medications called tumor necrosis factor (TNF) an-
tagonists [71–73]. Its brand name is Olumiant. It has been tested for
phase III trial for treatment of COVID-19 [20,21].
5.1. History of baricitinib
European Committee for Medicinal Products for Human Use (CHMP)
approved for using Baricitinib in the treatment of RA in February 2017.
Baricitinib was approved in the United States for the treatment of rheu-
matoid arthritis in May 2018 [74]. In April 2020 Eli Lilly announced they
Scheme 5. Direct synthetic route to BCX4430.
Fig. 5. Non-obligate chain termination of hepatitis C via in vitro RNA-
dependent, template-directed RNA synthesis by incubation with BCX4430-TP.
Lane 5 and 8 depicts chain termination due to incorporation of BCX4430.
Lanes 4 and 7 show 30-deoxyATP, an acknowledged obligate chain terminator
positive control. The pattern of RNA oligomers shown in absence of inhibitors or
in presence of normal nucleotides is represented in lane 6. Reproduced with
permissions from (ref [5]) Nature 508, 402–405 (2014). Copyright: Springer
Nature, 2014.
Fig. 6. Structure of favipiravir.
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were investigating the use of Baricitinib for treating COVID-19 patients.
The drug’s anti-inflammatory activity is expected to act on the inflam-
matory cascade associated with COVID-19 [20,21].
5.2. Synthesis of baricitinib
Almost all the synthetic methods reported for the preparation of
Baricitinib employed important intermediates 2-(1-(ethylsulfonyl)
azetidin-3-ylidene)acetonitrile(1) and tert-butyl 3-(cyanomethylene)
azetidine-1-carboxylate(2). Eco-friendly synthetic routes are in demand
for intermediate 1 and 2. The synthesis of intermediates 1 and 2 was
associated with various drawbacks. For example, starting materials used,
harmful reagents, poor yields, production of a large amount of mixed salt
wastewater, hazardous to environment as well as not suitable for in-
dustrial production and produce inseparable by products.
Scheme 6. Synthesis of Favipiravir.
Scheme 7. Synthesis of Favipiravir.
Scheme 8. Synthesis of Favipiravir.
Scheme 9. Synthesis of Favipiravir.
Scheme 10. Synthesis of Favipiravir.
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5.3. Development of green and eco-friendly synthetic route
Alternate greener routes were tried to synthesize the intermediates 1
and 2. The cheaper material benzylamine was used as the starting ma-
terial instead of unstable reagent benzhydrylamine as benzhydrylamine
will be partly converted to dibenzophenone, to produce the intermediate
2 (Scheme 11) [75].
The cheaper and commercially available 2-(chloromethyl)oxirane (V-
1) and benzylamine (V-2), which was converted to 1-benzylazetidin-3-ol
(V-3). Compound V-3 was then converted via reduction reaction and N-
Boc protection to afford compound V-4, which was reacted with 2,2,6,6-
tetramethylpiperidine-1-oxyl (TEMPO) to obtain intermediate V-5 by
two different methods. Then intermediate V-5 was employed to afforded
key intermediates tert-butyl 3-(cyanomethylene)azetidine-1-carboxylate
(V-6, 2) and 2-(1-(ethylsulfonyl)azetidin-3-ylidene)acetonitrile (V-8, 3)
successively underwent wittig reaction, deprotection, and hinsber re-
actions [75].
5.4. Clinical importance
Baricitinib was approved in February of 2017 to treat adult patients
suffering from moderate to severe active rheumatoid arthritis [71].
Rheumatoid arthritis is a progressive autoimmune disease commonly
associated with pain, disability, and damage of joints. As the disease
progresses it leads to swelling in joints, deformations and may lead to
impairment in functioning [70,71]. It reduces quality of life [76,77].
While there are other anti-rheumatic drugs (DMARDs) available for
treatment, patients have not received adequate therapeutic responses to
these drugs. Baricitinib was shown to have significant anti-inflammatory
effects in animal models of inflammatory arthritis [76]. Trials are under
process if Baricitinib could help treat the complications of Covid-19 in
patients [21].
6. Baloxavir
Baloxavir (Fig. 8B) is an active form of the prodrug baloxavir mar-
boxil (7A). It is completely converted into the active metabolite Baloxavir
from the hydrolysis of prodrug baloxavir marboxil. Baloxavir inhibits
influenza virus replication by inhibiting the activity of endonuclease
protein (polymerase acidic protein) essential for the replication of the
virus. Recently, Baloxavir has been also tested in one phase 2 clinical trial
and two phase 3 clinical trials for their clinical efficacy and safety to treat
acute uncomplicated influenza. However, headaches, nauseas, naso-
pharyngitis, bronchitis and diarrhoea were observed as themost common
side-effect of the Baloxavir during clinical trials. Volume distribution
(Vd) of Baloxavir is 1, 180 L and it has about 93% binding of affinity to
the proteins. Half-life and clearance of Baloxavir is 79.1h and 10.3 L/h
respectively. Metabolism of Baloxavir takes place through UGT1A3 with
a little participation of CYP3A4. Moreover, administration of radio-
labelled Baloxavir maraboxil shown to be excreted mainly through faeces
(80.1%) and 14.7% through urine. Whilst, 3.3% excreted as Baloxavir
[78].
Fig. 7. Structure of baricitinib.
Scheme 11. Green and eco-friendly synthetic route for intermediate 3. Reproduced from Ref. [74] under Creative Commons Attribution License 4.0.
Fig. 8. Chemical structure of (A) Baloxavir marboxil and (B) Baloxavir.
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6.1. History of baloxavir
Currently new antiviral drugs are going under different phases of
clinical trials to cope with the increasing resistance of the drugs to the
influenza versus. Among them Baloxavir is a newly developed novel drug
developed to treat influenza A or B. Compared to other drugs which block
release of virus from the infected cell such as neuraminidase inhibitor,
Baloxavir inhibits influenza virus replication by stopping synthesis of
mRNA. Therefore, Shionogi and Roche made a memorandum of under-
standing in February 2016 for the development and global commercial-
ization of Baloxavir. As per this agreement Shionogi receives advance
payment from Roche with the condition to receive future payments
received from the development and commercialization as well as roy-
alties from Baloxavir sale. Moreover, Shionogi holds full commerciali-
zation rights of Baloxavir in Japan and Taiwan with few co-promotion
rights in the USA. Whilst, Roche hold global commercialize right of
Baloxavir except Japan and Taiwan [22].
Furthermore, Shionogi began recruitment for a randomised, multi-
national and double-blind phase III trial (CAPSTONE-2; NCT02949011)
in December 2016. The objective of this trial was to study the efficacy of
Baloxavir for the treatment of both adult and children (more than 12
year) patients of influenza A and B compared to placebo and oseltamivir.
Patients recruited for trials have compromised immune systems having
different diseases or disorders such as chronic lung diseases, heart dis-
eases, asthma or metabolic, blood, endocrine and neurological disorders.
Besides, patients of age more than 65 years were also recruited for the
clinical trials. Additionally, Shionogi started an open-label phase III trial
(JapicCTI-173811) on healthy children of age less than 12 years with
influenza A or B for studying the efficacy and safety. Children having
influenza A or B was given one dose of Baloxavir 2% [22]. Recently, due
to its novel significance to treat influenza A or B, Baloxavir was granted
first global approval on 23 February 2018 in Japan to treat paediatric and
adult patients suffering from influenza A or B. It is prescribed to take one
dose of Baloxavir as the symptoms become evident. However, dosages
strength could be optimised both in children and adults based on their
body weight. It is recommended 40 mg as a single dose for the patient
weighing between 40 and 80 Kg, and 80 mg as a single dose for the
patient weighing more than 80 Kg [22].
6.2. Mode of action
Mode of action of Baloxavir is unique compared to other available
drugs for treating the influenza virus. Furthermore, single dose regimen
together with its orally administrable property is an important advantage
of the Baloxavir [79]. Baloxavir, inhibits influenza virus replication by
inhibiting the activity of enzyme “polymerase acidic protein”. This
enzyme is essential to acts on capped 50 RNA primers for the transcription
of the viral genetic material (RNA) [80]. Therefore, Baloxavir inhibit the
action of “polymerase acidic protein” which prevent transcription and
consequently stop replication of the virus [81].
7. Conclusions and future outlooks
In this article five promising complex small drug molecules Remde-
sivir, Galidesivir, Favipiravir, Baricitinib, and Baloxavir of clinical
importance have been reviewed. As per the current available literature a
detailed outlook of each drug has been presented in terms of history,
synthesis methods and mode of action. Study shows that all the described
drugs have been considered to repurpose for the treatment of COVID-19
disease. Especially Remdesivir and Favipiravir have shown good efficacy
in clinical trials. These drugs bind to the RdRp of the SARS-CoV-2 strain
and thus inhibit the viral action. Hence, these drugs may be useful for its
treatment. Further, no toxicity measures are required as these drugs have
been tested previously for other diseases.
However, Remdesivir was mainly developed to treat Ebola virus
infection. Furthermore, early in-vitro clinical results show that high
concentration of Favipiravir required compared to Remedisivir to treat
SARCoV-2. Moreover, Trials are under process for repurposing Galide-
sivir and Baricitinib to treat the complications of Covid-19 in patients.
Whereas, Baloxavir has been developed to treat different types of influ-
enza. The described drugs have shown interesting antiviral activities, yet
the scope for the further modification still remains required to improve
the potency of the drugs so that one drug can be used against multiple
targets. Also, the reported methods for the construction of the described
drugs can be modified because these protocols involve the multistep
conventional approaches, use of expensive and toxic reagents, etc.
Therefore, there is a significant room for the incorporation of strategies
following green chemistry principles in the productions of such highly
valuable drug molecules. Applications of green chemistry principles may
result in use of (a) least chemical and reagents, (b) lesser solvents, and (c)
least or no production of toxic and product harmful for the environment
and having adverse effects on human health. Also, there is substantial
scope for the use of visible light mediated synthesis and continuous flow
synthesis as well as alternative energy sources such as microwaves and
ultrasound radiations for the fabrication of these drugs. We anticipate
that in due course of time the research community will work to improve
the potency of these drugs by modifying the various functional groups
present or by introducing the new functionalities through post-
functionalization approaches.
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